Ask VialBase
Research

DehydraTECH-CBD + DehydraTECH-Semaglutide Combination Phase 1b in Obesity and Type 2 Diabetes — VialBase Research

Trial Summary

Phase 1b, randomized, open-label, active-controlled, parallel, multiple-dose study comparing the safety, pharmacokinetics, and efficacy of DehydraTECH-enhanced oral Semaglutide and cannabidiol (CBD) alone and in combination against Rybelsus and Tirzepatide in overweight/obese, pre- and type 2 diabetic participants.

Design

  • Type: Randomized, open-label, active-controlled, parallel, multiple-dose
  • Population: Adults with pre-diabetes or T2DM, overweight or obese
  • Enrollment: 148 participants
  • Arms:
    • Arm 1: DehydraTECH-CBD alone
    • Arm 2: DehydraTECH-semaglutide alone
    • Arm 3: DehydraTECH-CBD + DehydraTECH-semaglutide combination
    • Arm 4: Rybelsus (reference oral semaglutide)
    • Arm 5: Tirzepatide (active control)
  • Duration: Multiple-dose, ~7 months enrollment window

Key Outcomes

Trial completed July 2025. Primary endpoint: adverse event frequency. Results pending publication at time of ingest. Lexaria’s DehydraTECH platform is marketed as a lipophilic-drug oral delivery enhancer — the core thesis is that DehydraTECH-semaglutide will improve oral bioavailability over Rybelsus.

Significance for Peptide Research

This is one of the first formal trials pairing a cannabinoid (CBD) with an oral semaglutide formulation in a population relevant to obesity + T2DM. Two signals worth watching when results publish:

  1. Oral delivery enhancement: if DehydraTECH-semaglutide demonstrably outperforms Rybelsus on PK, it validates lipid-carrier oral peptide delivery as a real platform bet and has implications for other oral peptides beyond semaglutide.
  2. CBD + GLP-1 interaction: CBD’s metabolic and anti-inflammatory effects have been hypothesized to complement GLP-1 appetite suppression. A formal safety + efficacy readout in a combined arm is novel.

The trial is industry-sponsored by Lexaria Bioscience and serves commercial validation of their platform, so readers should weight results accordingly when they publish.

See Also